Two ARG1 inhibitors, NOHA and nor-NOHA, have been tested in various cancer models and can diminish the immuno-inhibitory function of MDSCs and improve anti-tumor T cell response (Geiger et al., 2016). The gene discussed is ARG1; the disease is neoplasm.